Morgan Stanley is out with its report today on HCP HCP, initiating HCP at Equal-weight.
In its report, Morgan Stanley writes, "Initiate coverage with an Equal-weight rating and a $38 price target, representing 14% total return potential. We view HCP today as the rare combination of a blue chip REIT offering a high dividend yield (5.5%). Risks of Medicare reimbursement cuts present a medium-term overhang, in our view."
At the time of posting, shares of HCP were trading at $34.62, down 1.14% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in